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Abstract
Background The mammalian target of rapamycin (mTOR)
inhibitor everolimus is used in the treatment of breast
cancer, neuroendocrine tumors, and renal cancer. The
approved 10 mg once-daily dose is associated with con-
siderable adverse effects and it has been suggested that
these are associated with the maximum concentration
(Cmax) of everolimus. Twice-daily dosing might be an
alternative strategy with improved tolerability; however, a
direct pharmacokinetic comparison of 10 mg once-daily
with 5 mg twice-daily dosing is lacking.
Methods We performed a prospective, randomized, phar-
macokinetic, crossover trial comparing everolimus 10 mg
once daily with 5 mg twice daily. Patients received the first
dose schedule for 2 weeks and then switched to the alter-
native regimen for 2 weeks. Pharmacokinetic sampling
was performed on days 14 and 28.
Results Eleven patients were included in the study, of
whom 10 were evaluable for pharmacokinetic analysis. On
the 10 mg once-daily schedule, Cmax, minimum concen-
tration (Cmin), and area under the concentration-time curve
from time zero to 24 h (AUC24) were 61.5 ng/mL [mean
percentage coefficient of variation (CV%) 29.6], 9.6 ng/mL
(CV% 35.0), and 435 ng h/mL (CV% 28.1), respectively.
Switching to the 5 mg twice-daily schedule resulted in a
reduction of Cmax to 40.3 ng/mL (CV% 46.6) (p = 0.013),
while maintaining AUC24 at 436 ng h/mL (CV% 34.8)
(p = 0.952). Cmin increased to 13.7 ng/mL (CV% 53.9)
(p = 0.018). The overall reduction in Cmax was 21.2 ng/
mL, or 32.7%. The Cmax/Cmin ratio was reduced from 6.44
(CV% 36.2) to 3.18 (CV% 35.5) (p\ 0.001).
Conclusions We demonstrated that switching from a once-
daily to a twice-daily everolimus dose schedule reduces
Cmax without negatively impacting Cmin or AUC24. These
results merit further investigation of the twice-daily
schedule in an effort to reduce everolimus toxicity while
maintaining treatment efficacy.
Registration This trial was registered in the EurdaCT
database (2014-004833-25) and the Netherlands Trial
Registry (NTR4908).
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Key Points
The approved 10 mg once-daily everolimus dose is
associated with considerable adverse effects, which
have been suggested to be associated with maximum
concentration (Cmax).
Twice-daily dosing could lower Cmax and thereby
lead to improved tolerability.
As a direct pharmacokinetic comparison of 10 mg
once daily with a 5 mg twice-daily regimen was
lacking, we performed a prospective, randomized,
pharmacokinetic, crossover trial in cancer patients to
compare the pharmacokinetics of everolimus 10 mg
once daily with 5 mg twice daily.
Switching to twice-daily everolimus dosing reduced
Cmax without negatively impacting minimum
concentration or area under the concentration-time
curve from time zero to 24 h. These results merit
further investigation of the twice-daily schedule in
an effort to reduce everolimus toxicity while
maintaining treatment efficacy.
1 Background
Everolimus is a mammalian target of rapamycin (mTOR)
inhibitor approved for the treatment of renal cell carcinoma
[1], neuroendocrine tumors [2], and hormone receptor
(HR)-positive, human epidermal growth factor receptor 2
(HER2)-negative breast cancer [3]. Inhibition of mTOR
has been shown to enhance the effectiveness of hormonal-
based therapies for breast cancer patients who have
become resistant to endocrine therapy [4].
The BOLERO-2 trial showed that the addition of ever-
olimus to exemestane increased progression-free survival
in patients with HR-positive, HER2-negative advanced
breast cancer compared with placebo [3]. This improve-
ment from 4.1 to 11.1 months resulted in a hazard ratio of
0.38 (95% confidence interval 0.31–0.48, p\ 0.0001) in
the final analysis [5]. Nonetheless, the everolimus 10 mg
once-daily dose in combination with exemestane 25 mg
once daily resulted in significant adverse events (AEs) (any
grade): 56% of patients developed stomatitis, 36% devel-
oped rash, 33% developed fatigue, and 30% developed
diarrhea. These events were severe (grade 3) in 8, 1, 3, and
2% of patients, respectively, and a considerable 19% of
patients discontinued treatment due to toxicity. Moreover,
a meta-analysis of over 900 patients included in various
everolimus phase II trials by Ravaud et al. estimated the
overall incidence of stomatitis at 57% (any grade) and the
incidence of severe (grade 3–4) stomatitis at 6% [6].
Adverse effects, particularly stomatitis, have been shown
to be related to pharmacokinetic exposure to everolimus
[6, 7]. Specifically, these AEs may be associated with high
maximum plasma concentrations (Cmax) [8]; thus, reducing
Cmax while maintaining efficacious trough concentrations
(Cmin) could be an effective method of optimizing the
treatment of everolimus by reducing toxicity yet retaining
efficacy.
Generally, the various pharmacokinetic parameters
Cmin, Cmax, and area under the whole blood concentration-
time curve (AUC) will be strongly interrelated (i.e. a
higher dose will increase all three, and, conversely, a dose
reduction will reduce all three). However, in contrast to
lowering the once-daily dose (the current strategy to
reduce toxicity in clinical practice), switching to a twice-
daily schedule could specifically reduce Cmax without
negatively impacting Cmin or AUC, and thereby theoret-
ically reduce toxicity while not reducing efficacy. A
strategy to reduce the Cmax/Cmin ratio could be the use of
an extended- or sustained-release formulation [8], or
splitting the intake moments from once daily to twice
daily.
We hypothesized that given the pharmacological prop-
erties of everolimus, the latter approach could reduce the
Cmax while maintaining the Cmin and total exposure, mea-
sured as AUC at similar levels. This could lead to reducing
the Cmax/Cmin ratio without the need to develop a new
sustained-release formulation, thereby preventing a costly
patent extension. To test this hypothesis, we performed a
randomized, pharmacokinetic, crossover trial of everolimus
10 mg once daily versus 5 mg twice daily in cancer
patients.
2 Methods
2.1 Study Design
We performed a prospective, multicenter, randomized,
crossover trial. An overview of the trial design is given in
Fig. 1. Patients were randomized to start with either a 10
mg once-daily or 5 mg twice-daily dose, and each patient
was treated for at least 2 weeks with each dose schedule.
Patients were instructed to take everolimus daily, at the
same time each day, with a low-fat meal. Patients requiring
a dose reduction due to toxicity were considered non-
evaluable for the pharmacokinetic endpoint and were
replaced.
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2.2 Patient Population
Patients with histopathologically confirmed advanced
cancer for whom everolimus was considered standard of
care were eligible for inclusion. Further inclusion criteria
were age[18 years, and minimal acceptable safety labo-
ratory values, defined as absolute neutrophil count
C1.5 9 109/L, platelet count of[100 9 109/L, bilirubin
\1.5 times the upper limit of normal (ULN), aspartate
aminotransferase (AST) and alanine aminotransferase
(ALT) \2.5 times the ULN, creatinine \1.5 times the
ULN, or creatinine clearance[50 mL/min.
Exclusion criteria were the use of any concomitant
medication (including over-the-counter and herbal medi-
cation) that would induce or inhibit the function of cyto-
chrome P450 (CYP) 3A4.
2.3 Pharmacokinetics
At the end of each 2-week period (days 14 and 28), blood
samples were collected for pharmacokinetic analysis. In the
10 mg once-daily schedule, samples (3 mL) were collected
at 0, 0.5, 1, 2, 3, 4, 5, 6, 12, and 24 h after drug adminis-
tration, while in the 5 mg twice-daily schedule sampling
times were 0, 0.5, 1, 2, 3, 4, 5, 6, 12, 12.5, 13, 14, 15, 16,
and 24 h after ingestion of the last dose. On the days of
pharmacokinetic sampling, everolimus was taken con-
comitantly with a low-fat meal. Whole-blood everolimus
concentrations were measured using a validated liquid
chromatography tandem mass spectrometry (LC-MS/MS)
method.
2.4 Bioanalysis
A 200 lL aliquot of whole blood was transferred to an
Eppendorf tube, and a 40 lL volume of 75 ng/mL internal
standard (13C,2H3-everolimus) in methanol and 1.0 mL of
tert-butyl methyl ether was added. Samples were vortexed
and shaken for 5 min at 1500 rpm, before being cen-
trifuged at 23,100g for 5 min. Liquid-liquid extraction was
then followed by snap freezing the samples and transfer-
ring the organic phase to a new Eppendorf tube. The
organic phase was then evaporated under a gentle stream of
nitrogen. The residue was reconstituted in water with
20 mM ammonium formate and methanol (1:1, v/v), of
which 5 lL was injected in the LC-MS/MS system [HPLC
1100 series (Agilent) and API3000 mass spectrometer
(Sciex)]. Chromatographic separation was performed on a
Sunfire C18 column (Waters) using 20 mM ammonium
formate in water and a gradient of 50–100% methanol. The
bioanalytical assay was validated in accordance with US
FDA guidelines for bioanalytical method validation. The
analytical range was 1–100 ng/mL. Inter-run and intra-run
precision were B8.5%, and overall and intra-run bias was
within ±11%. Carryover was B5.3% of the lower limit of
quantitation (1 ng/mL), and the matrix effect (quantified as
the CV of the internal standard normalized matrix factor)
was B1.7%.
2.5 Study Endpoint
The primary endpoint of this trial was to describe and
compare the pharmacokinetics of everolimus in whole
blood after a 10 mg once-daily dose and a 5 mg twice-
daily dose. Parameters of particular interest were Cmax,
Cmin, and AUC from time zero to 24 h (AUC24). The safety
of both dose schedules was included as an exploratory
endpoint.
2.6 Safety Assessments
Recording of AEs, physical examination, and hematology
and blood chemistry assessments were performed every
2 weeks. The incidence, severity, and start and end dates of
all serious AEs (SAEs) and non-serious AEs were recor-
ded. AEs were graded according to the Common Termi-
nology Criteria for Adverse Events (CTCAE) version 4.02.
2.7 Statistics
All statistical analyses were performed in R version 3.3.2
(R Project, Vienna, Austria) [9]. Pharmacokinetic param-
eters were calculated using non-compartmental analysis.
Cmax was defined as the higher of the two observed peaks
Fig. 1 Trial design. Patients were randomized to start with a 2-week
period of an everolimus 5 mg twice-daily dose or an everolimus
10 mg once-daily dose. Pharmacokinetic sampling was performed
after each 2-week period (days 14 and 28). qd once daily, bid twice
daily
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for the twice-daily schedule, while Cmin was defined as the
average of t = 0 and 24 h, and t = 0, 12, and 24 h, for the
once-daily and twice-daily schedules, respectively. Two-
sided paired t-tests were used to assess the difference
between the calculated pharmacokinetic parameters of the
two dose schedules.
Given the descriptive nature of the pharmacokinetic
endpoint in this pilot study, it was unfeasible to perform a
meaningful formal power analysis; hence, no calculation
for the exact number of patients is given. The proposed
number of patients is therefore based on comparable
pharmacokinetic pilot studies and a conservative estimate
of the number of eligible patients. However, in an
exploratory analysis, it was calculated that with a sample
size of five evaluable subjects in each sequence group (a
total sample size of ten subjects), a 2 9 2 crossover design
will have 80% power to detect a difference in mean Cmax of
17.5 ng/mL (the difference between a mean, l1, of 61 ng/
mL for one treatment and a mean, l2, of 43.5 ng/mL for
the other treatment), assuming that the Hmean standard
error is 12.021 (the standard deviation of differences, rd, is
17 [10] using a two-group t test with a 0.050 two-sided
significance level. The sample size calculation was per-
formed using the nQuery Advisor software package version
7.0 (Statistical Solutions Ltd).
2.8 Study Conduct and Registry
This trial was conducted in accordance with the World
Medical Organization Declaration of Helsinki, compliant
with Good Clinical Practice, and approved by the Medical
Ethics Committee of each participating medical center
(The Netherlands Cancer Institute and Erasmus MC Cancer
Institute). All patients provided written informed consent
prior to enrollment in the study. This trial was registered in
the EudraCT database (2014-004833-25) and the Nether-
lands Trial Registry (NTR4908).
3 Results
3.1 Patient Population
In total, 11 patients provided written informed consent, of
whom four had breast cancer, four had renal cell cancer,
and three had neuroendocrine tumors. One patient with
breast cancer withdrew consent after pharmacokinetic
sampling on day 14, and the remaining 10 patients were
evaluable in both dose schedules. No patients required a
dose reduction. An overview of the characteristics of the
evaluable patients is provided in Table 1. The four breast
cancer patients used everolimus in combination with
exemestane 25 mg, in accordance with the summary of
product characteristics. Of all the enrolled patients, 30%
had already received everolimus prior to inclusion in the
trial.
3.2 Pharmacokinetics
Absolute and relative change in Cmax for each individual
patient are displayed in Table 2. The mean reduction in
Cmax achieved by switching from a once-daily to a twice-
daily dose was 21.2 ng/mL, or 32.7% (p = 0.013). All but
one patient showed a reduction in Cmax. For this patient,
only one of the two peak values on the twice-daily schedule
(79.4 and 40.2 ng/mL) was above the Cmax of the once-
daily schedule (56.9 ng/mL); however, the highest of both
peaks was used for calculation of the change in Cmax.
An overview of the pharmacokinetic parameters for
each of the dose schedules is provided in Table 3. Changes
in AUC24 and time to Cmax (Tmax) were not statistically
significant (p = 0.70 and 0.95, respectively). Box plots
comparing selected pharmacokinetic parameters of the
once-daily and twice-daily schedules are shown in Fig. 3.
Interpatient variability [percentage coefficient of varia-
tion (CV%)] for AUC24,Cmax, andCmin were 28.1, 29.6, and
36.2%, respectively, for the 10mg once-daily dose level, and
35.5, 46.6, and 53.9%, respectively, for the 5 mg twice-daily
dose level. Intrapatient variability (quantified as an intrapa-
tient CV% on t = 0 and t = 24 for each schedule) was rel-
atively small, with a mean intrapatient CV of 11.1% on the
twice-daily schedule and 6.8% on the once-daily schedule.
The hematocrit values of patients (which could impact
the whole-blood pharmacokinetics of everolimus) did not
Table 1 Baseline characteristics of evaluable patients (n = 10)
Characteristic n (%) or mean (range)
Sex
Male 5 (50%)
Female 5 (50%)
Age (years) 56 (43–78)
Height (cm) 171 (161–192)
Weight (kg) 76 (52–92)
WHO performance status
0 4 (40%)
1 6 (60%)
Tumor type
Breast 3 (30%)
Renal 4 (40%)
Neuroendocrine 3 (30%)
Previous systemic therapy
Chemotherapy 6 (60%)
Targeted therapy 5 (50%)
Endocrine therapy 4 (40%)
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show marked changes between the two pharmacokinetic
visits. Median fold change was 1.05, ranging from
0.97–1.17. Overall mean hematocrit during the trial was
36.6%.
Five patients were randomized to each treatment arm.
The randomization sequence did not seem to impact the
outcome of the primary endpoint as the absolute and rel-
ative mean Cmax reductions in the once-daily to twice-daily
arm were 19.4 ng/mL and 26.8%, compared with 23.0 ng/
mL and 38.5% in the twice-daily to once-daily sequence
arm.
3.3 Adverse Events
An overview of all treatment-related AEs is provided in
Table 4. Only one patient did not experience any treat-
ment-related AEs. The most common event was oral
stomatitis (in all cases limited to grade 1). Only one grade 3
event (ALT elevation) and two grade 2 events (neuropathy
and increased AST) occurred during the trial period. Due to
the low number of events in the trial period, no distinct
differences in toxicity between the two dosing arms or
exposure–safety relationships could be distinguished.
4 Discussion
The hypothesis of this study was that switching patients
from a 10 mg once-daily dose to a 5 mg twice-daily dose
would lead to a reduction in Cmax, which is probably
responsible for most of the dose-limiting toxicities, while
still maintaining AUC and Cmin, to guarantee similar effi-
cacy. We have shown that splitting everolimus intake
results in a large reduction in Cmax and a modest, yet sta-
tistically significant, increase in Cmin (Table 2; Figs. 2, 3).
This resulted in an approximately 50% reduction in the
Cmax/Cmin ratio of 6.44 on the once-daily schedule, to 3.18
on the twice-daily schedule (p\ 0.001).
No significant difference in total exposure measured as
AUC was detected by splitting the dose into a 5 mg twice-
daily regimen. This was the intended outcome and was in
concordance with the pharmacokinetic data in the phase I
study, which showed no dose-dependent change in
bioavailability over a dose range of 5–70 mg [10]. Subse-
quently, these results support the view that a switch from
10 mg once daily to 5 mg twice daily is feasible and could
improve specific pharmacokinetic parameters without
affecting overall exposure.
Previous studies have shown a large interpatient vari-
ability in the pharmacokinetics of everolimus [7, 10–12].
Our trial confirms this high interpatient variability, with
CVs ranging from 28.1 to 53.9% (Table 2). CVs were
numerically higher in the twice-daily arm than in the once-
daily arm. This difference is most likely driven by the
single outlier patient (see Table 4) who had an increased
Cmax on the twice-daily schedule. As food is known to
Table 2 Absolute and relative change in Cmax after switching from
10 mg once daily to 5 mg twice daily for each individual patient
(concentration and percentage)
ID Cmax reduction (ng/mL)
a Cmax reduction (%)
1 5.5 12.1
2 14.9 48.1
3 35.1 47.5
4 21.1 47.4
5 3.4 5.5
6 -22.5 -39.5
7 30.1 44.1
8 48.4 67.6
9 31.4 47.4
10 44.5 46.6
Mean 21.2 ng/mL 32.7%
Cmax maximum concentration
a Cmax is defined as the highest of the two observed peaks for the
twice-daily schedule
Table 3 Selected
pharmacokinetic properties of
everolimus in the 10 mg once-
daily and 5 mg twice-daily
schedules
Pharmacokinetic parameter 10 mg once daily 5 mg twice daily p value
Cmax (ng/mL)
a 61.5 (29.6) 40.3 (46.6) 0.013
Tmax (h) 1.4 2.2 0.703
Cmin (ng/mL)
b 9.6 (35.0) 13.7 (53.9) 0.018
AUC24 (ng*h/mL) 435 (28.1) 436 (34.8) 0.952
Cmax/Cmin ratio 6.44 (36.2) 3.18 (35.5) <0.001
Bold values indicate statistically significant p values
Data are expressed as mean (CV%)
Cmax maximum concentration, Tmax time to Cmax, Cmin minimum concentration, AUC24 area under the
concentration–time curve from time zero to 24 h
a Cmax is defined as the higher of the two observed peaks for the twice-daily schedule
b Cmin is defined as the average of t = 0 and 24 h, and t = 0, 12, and 24 h, for the once-daily and twice-
daily schedules, respectively
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affect the pharmacokinetics of everolimus [13], patients
were instructed to take everolimus with a low-fat meal
during the study period. To further reduce a possible effect
of this and other environmental factors on the pharma-
cokinetic variability of everolimus, we used a crossover
design for the current study. Using this design, only
intrapatient pharmacokinetic variability could possibly
influence the outcome.
As shown in Fig. 2, the Cmax achieved on the twice-
daily schedule in the evening seemed lower compared with
the Cmax in the morning. This is most likely due to the
larger meal size in the evening as food is known to reduce
the absorption of everolimus [13]
In the current study, everolimus was well-tolerated in
both dose regimens; however, some patients had already
received everolimus prior to enrollment. This limits the
Table 4 Toxicity data per dose
schedule, graded according to
CTCAE version 4.02 (only
treatment-related toxicities are
shown)
Adverse event 5 mg twice daily 10 mg once daily
Any grade (n) Grade C3 (n) Any grade (n) Grade C3 (n)
Stomatitis 2 0 2 0
AST increase 1 0 0 0
ALT increase 0 1 0 0
Neuropathy 1 0 0 0
Fatigue 1 0 0 0
Nausea 1 0 0 0
Constipation 0 0 1 0
Dry skin 2 0 0 0
Dry mouth 1 0 0 0
Pruritus 0 0 1 0
CTCAE Common Terminology Criteria for Adverse Events, AST aspartate aminotransferase, ALT alanine
aminotransferase
Fig. 2 Whole-blood concentration-time curves (mean ? standard deviation) of the 10 mg once-daily (left) and 5 mg twice-daily (right) dose
schedules (n = 10)
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comparison of toxicity between the two dose regimens as
most everolimus-associated AEs occur soon after the ini-
tiation of therapy [14]. Moreover, in the current trial,
patients were only treated on each dose schedule for a short
duration of merely 2 weeks.
Everolimus Cmin has been linked to treatment efficacy in
several studies. An analysis of 44 renal cell carcinoma
patients proposed a threshold for efficacy of 14.1 ng/mL
[15]. Although not statistically significant, a difference in
progression-free survival of 13.3 versus 3.9 months was
seen. In pediatric oncology, everolimus is administered
based on whole-blood concentrations, and a Cmin window
of 5–15 ng/mL is used as the pharmacokinetic target [16].
In pancreatic neuroendocrine tumors, median progression-
free survival was 22.7 months in patients with a Cmin of
10–30 ng/mL, compared with only 13.8 months in patients
with a Cmin\10 ng/mL [6]. In a meta-analysis of published
phase II trials in various tumor types, a twofold increase in
Cmin increased the probability of tumor size reduction by
40%, and reduced the risk of progression-free survival
events by 10% [6]. These findings underscore the need to
maintain Cmin levels. Fortunately, the current strategy of 5
mg twice-daily dosing increased Cmin compared with once-
daily dosing, potentially leading to a better progression-
free survival. However, a prospective clinical trial is nee-
ded to conclusively demonstrate a reduction in toxicity and
improved efficacy for the everolimus twice-daily admin-
istration schedule.
A drawback of switching to a twice-daily dose schedule
might be that it could reduce treatment compliance.
However, the effect of once-daily dosing on adherence has
been shown to be modest in other therapeutic areas (e.g.
only a 2.9% increase in adherence was seen in a meta-
analysis of antiretroviral drugs) [17]. Moreover, it could
also be argued that a reduction in toxicity could help
maintain treatment adherence and even prevent dose
reductions or treatment discontinuation, which are common
in everolimus treatment [3, 7].
Limitations of the current study include its limited size
and duration and the fact that patients could have already
received everolimus prior to enrollment. Although the
endpoint of a reduced Cmax/Cmin ratio has been achieved,
the relationship between this ratio and toxicity cannot be
assessed based on these data.
An alternative strategy to manage toxicity could be to
individualize the everolimus dose based on measured Cmin
levels, also known as therapeutic drug monitoring. Given
the high interpatient variability in exposure [10] and the
established exposure–efficacy and exposure–toxicity rela-
tionships, this would be a rational approach. Moreover, this
has already been implemented in everolimus therapy in
transplantation medicine [18] and pediatric oncology [16].
Twice-daily dosing could be combined with therapeutic
drug monitoring to further manage the pharmacokinetic
exposure in everolimus treatment, and, interestingly, in
transplantation medicine, everolimus is already routinely
Fig. 3 Box plots of Cmax, Cmin, and AUC24 for both dose schedules.
Cmin is defined as the average of t = 0 and 24 h, and t = 0, 12, and
24 h, for the once-daily (orange boxes) and twice-daily schedule
(green boxes), respectively. Cmax was defined as the higher of the two
observed peaks for the twice-daily schedule. Cmax maximum
concentration, Cmin minimum concentration, AUC24 area under the
concentration-time curve from zero to 24 h, qd once daily, bid twice
daily
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administered in a twice-daily schedule, albeit at a lower
total dose [18].
5 Conclusion
This randomized, pharmacokinetic, crossover study in
cancer patients indicates that switching from a 10 mg once-
daily to a 5 mg twice-daily dose schedule significantly
reduces everolimus Cmax without negatively impacting
Cmin or AUC24. These results merit further investigation of
the everolimus twice-daily schedule in oncology in an
effort to reduce everolimus toxicity while maintaining
treatment efficacy.
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